Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Public ClinicalTrials.gov record NCT00528983. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Study identification
- NCT ID
- NCT00528983
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Interventions
- Subcutaneous (SC) Azacitidine Drug
- Oral Azacitidine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2007
- Primary completion
- Jul 30, 2013
- Completion
- Apr 4, 2016
- Last update posted
- Nov 7, 2019
2007 – 2016
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32610-0277 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Central Indiana Cancer Centers | Indianapolis | Indiana | 46219 | — |
| Kansas University Medical Center | Westwood | Kansas | 66205 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21231-1000 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Kansas City VA Medical Center University of Kansas Medical Center | Kansas City | Missouri | 64128 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| New York Oncology Hematology P.C. | Albany | New York | 12206 | — |
| Institute for Translational Oncology Research IRB | Greenville | North Carolina | 29605 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology Cancer Care | Austin | Texas | 78731 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| HOAST | San Antonio | Texas | 78229 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-4417 | — |
| Yakima Valley Memorial Hospital/ North Star Lodge | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00528983, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2019 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00528983 live on ClinicalTrials.gov.